SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending due to increased interest in the quantum computing sector, amplified by news of government contracts and private sales. Community discussions revolve around the company's high valuation relative to current revenue, creating a debate between bullish long-term potential and bearish overvaluation concerns. Recent price action and volume spikes are also contributing to the stock's increased visibility.

Q/C Technologies, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of drug products to extend healthy lifespan. It focuses on developing two novel therapeutic platforms, MyMD-1 and SUPERA-CBD, which aim to treat the causes of disease rather than just addressing the symptoms. MyMD-1 is a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cytokines. SUPERA-CBD is a synthetic derivative of cannabidiol being developed to treat conditions such as epilepsy, chronic pain, depression, as well as neuroinflammatory and neurodegenerative diseases. The company was founded in 1989 and is headquartered in New York, NY.

Q/C Technologies Inc.

QCLS is trending amid discussions of its strategic shift towards quantum computing for cryptocurrency applications, particularly its partnership with LightSolver and potential for energy-efficient blockchain solutions. The community is comparing QCLS to other quantum and crypto stocks, with traders closely monitoring its low float and threshold list status. Speculation around news and potential contracts is also fueling interest.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum ($QBTS) is trending due to a recent surge, with the community discussing its strong balance sheet, real-world applications, and potential for further gains. Bullish sentiment is fueled by news of institutional interest and successful deployments of their quantum solvers. Some are drawing comparisons to the dot-com bubble, while others see $QBTS as a long-term play in the burgeoning quantum computing sector.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble Inc. is trending following the announcement of its partnership with AI search engine Perplexity, aimed at improving video discovery on the platform. Community members are discussing the potential benefits of integrating AI tools and Rumble's ties to the crypto world, with some speculating on the impact of this collaboration and potential future acquisitions. The stock's high short interest is also a hot topic, with some anticipating a potential squeeze.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

WAGMI is trending as the community rallies around its positive narrative and growing brand awareness, particularly on platforms like PUMP and SOL. Discussions highlight the token's strong community, recent acquisition of the '@wagmi' Instagram handle, and anticipation for potential breakouts. The focus remains on long-term growth and the overall 'WAGMI' (We're All Gonna Make It) ethos.

Quantum Computing, Inc. engages in developing novel algorithms and solutions utilizing quantum and quantum-inspired computing to solve difficult problems in various industries. It leverages its expertise in finance, computing, security, mathematics, and physics to develop commercial applications for the financial, security, and government sectors. The company was founded on July 25, 2001 and is headquartered in Hoboken, NJ.

Quantum Computing Inc

QUBT is trending amid a surge in quantum computing stocks, with community members discussing the company's potential in quantum-secure solutions. Some are pointing to a closed, oversubscribed private placement as a positive catalyst, while others express skepticism about the company's valuation and revenue. Traders are also weighing the potential impact of upcoming government actions related to quantum technology on the sector.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

AAPL is trending due to a mixed analyst outlook, highlighted by Jefferies downgrading the stock to Underperform while Morgan Stanley raised its price target significantly, sparking debate among investors about the company's valuation and future performance. The community is actively discussing the credibility of these differing analyses and their potential impact on Apple's stock price, while also eyeing potential upside catalysts such as strong iPhone 17 sales and long-term bullish positioning by institutions.

A multi-agent AI platform dissecting human nature’s first principles through iterative survival challenges and data-driven insights. Core dev has access to one of the founding partners of Two Sigma Ventures - the VC company of one of the biggest hedge funds in the world. Plans to raise seed round and scale after building organic foundation. Project devs are from academia space and are trying to bridge the gap between crypto and academia.

CortexZero

CortexZero is gaining attention as community members highlight its potential for a breakout, pointing to increased liquidity and strong buying activity. Conversations suggest a groundswell of support from early entrants, with many encouraging others to invest via Phantom Wallet. However, some users are also raising concerns about the token's concentration and low market cap.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IONQ is trending due to its position in the quantum computing sector, with community members actively discussing its high valuation and potential for future growth. News surrounding government funding and partnerships, including potential collaborations with NVIDIA, are also driving interest.  Additionally, some investors are closely watching for potential short squeezes and dilution.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending as investors discuss positive momentum and a potential short squeeze, with community members pointing to the stock being undervalued. Renewed optimism surrounds upcoming data releases, revenue potential and speculation around a buyout, while some traders monitor options activity for bullish signals. Community members are actively discussing resistance levels and expressing optimism about the stock's long-term potential amid volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Illumina to Join Pharma Partners for CDx Development on KRAS Biomarker

ILMN partners with pharma leaders to advance KRAS-focused companion diagnostics through its TruSight Oncology platform.

Is it a Prudent Move to Retain MYGN Stock in Your Portfolio Now?

Myriad Genetics expands oncology testing and launches new diagnostics, but inflation and rising competition weigh on its outlook.

MYGN Stock Might Gain on The Lancet Study Backing Precise MRD

Myriad Genetics' Precise MRD study in The Lancet shows ctDNA detection power in oligometastatic ccRCC, supporting oncology growth plans.

MYGN's GeneSight Test Proven Superior to TAU: Stock to Gain?

Myriad Genetics' GeneSight test outperforms treatment-as-usual in major depression, raising hopes for broader adoption and renewed stock momentum.

Compared to Estimates, Myriad (MYGN) Q2 Earnings: A Look at Key Metrics

The headline numbers for Myriad (MYGN) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Myriad Genetics (MYGN) Q2 Earnings and Revenues Surpass Estimates

Myriad (MYGN) delivered earnings and revenue surprises of +600.00% and +5.55%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Tempus AI Boosts R&D Efforts Through Wide-Ranging Product Launches

TEM expands its precision medicine arsenal with AI-powered tools, liquid biopsy tech and genome sequencing.

Tempus AI Eyes Positive Adjusted EBITDA in 2025: Is It Taking Shape?

Myriad (MYGN) Up 23.9% Since Last Earnings Report: Can It Continue?

Shares of Myriad Genetics&nbsp;slumped Wednesday as analysts issued a flurry of downgrades and price target cuts following a weak first quarter and lowered guidance.&nbsp;Wells Fargo downgraded the stock to ‘Equal Weight’ from ‘Overweight’, slashing its price target to $6 from $22.&nbsp;The stock plunged 41.3% to close at $4.27 on Wednesday.Analyst Brandon Couillard cited a “noisy” quarterly performance, reduced visibility, and low conviction in the company’s growth and margin outlook through 2026.Couillard warned that Myriad's revised 2025 guidance still implies a second-half inflection in volume growth, making the stock a “show-me story” that needs stronger execution and strategic clarity before investor sentiment can recover.Myriad reported Q1 revenue of $196 million, down 3% year-over-year. Adjusted for $16 million in headwinds, revenue grew 5%.&nbsp;The company posted a GAAP net loss of $0.1 million, supported by a $29 million tax benefit,&nbsp;while adjusted loss per share came in at $0.03.&nbsp;The company now expects full-year adjusted EPS in the range of a loss of $0.02 to a profit of $0.02, and trimmed its revenue outlook to $807–$823 million.Analyst sentiment turned broadly cautious.UBS lowered its price target to $7 from $16 while maintaining a ‘Neutral’ rating.Raymond James trimmed its target to $10 from $19 but kept an ‘Outperform’ rating, citing “somewhat soft” Q1 results and a 4% guidance cut under new CEO Sam Raha.&nbsp;Craig-Hallum cut its target to $18 from $29 but reiterated a ‘Buy,’ arguing that while recovery appears more difficult than expected, the stock’s valuation looks disconnected from longer-term potential.&nbsp;Wolfe Research also downgraded the stock to ‘Peer Perform.’Key weaknesses centered on the 20% drop in pharmacogenomics revenue, mainly tied to UnitedHealthcare's cut to GeneSight coverage.&nbsp;Oncology remained a bright spot, with hereditary cancer testing volumes in affected populations rising 11% year-over-year.Despite the cautious analyst tone, Stocktwits sentiment was marked as ‘extremely bullish’ amid ‘extremely high’ message volume.&nbsp;One user noted they were considering buying shares, calling the stock “cheap.”&nbsp;<stembedurl>https://stocktwits.com/Harunkaraca/message/613823074</stembedurl>Another reflected on owning Myriad in the past and questioned the growth outlook after GeneSight brought in just $31 million during the quarter. However, they still described the share price as attractive and cited a decent balance sheet, indicating they had bought after hours.<stembedurl>https://stocktwits.com/pilobious/message/613722246</stembedurl>Shares of Myriad have fallen over 68% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of stock price falling.

Myriad Genetics Shares Tank 41% On Analyst Downgrades, Weaker Guidance: Yet Retail Investors Remain Bullish

Analysts, including those from Wells Fargo, UBS, Raymond James, and Craig-Hallum, slashed their price targets and expressed concerns over the company's growth and execution challenges. 

Equity

Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Myriad Genetics, Inc.

0 to 25,000

25,000 to 50,000

50,000 to 75,000

75,000 to 100,000

How many jobs did the U.S. add in September? Vote below + drop your exact prediction in the comments. 
 
*Powered by Polymarket

Current Price	$7.56
Prev Close	$7.73
Open	$7.76
Dividend Yield	0.00%
50-Day Moving Average	$6.26
Beta	1.23
Avg. Volume	1.59M
PE Ratio	-1.76

52-Week High	$27.03
52-Week Low	$3.76
Market Capitalization	$703.42M
EPS (Annual)	-$1.41
Price to Book	1.81
Revenue Per Employee	$310,222.22
Enterprise Value/EBITDA	N/A

MYGN
Myriad Genetics, Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MYGN News

MYGN Myriad Genetics, Inc.